Premature ovarian insufficiency: hormone replacement is essential, not optional

Premature ovarian insufficiency (POI) affects approximately 1% of women before age 40, yet the average time from first symptoms to diagnosis is over two years — a delay that causes preventable harm to bone density, cardiovascular health, and psychological wellbeing. About 25% of women with POI have no hot flushes, making the diagnosis easy to miss unless FSH is checked in any woman under 40 with amenorrhoea or oligomenorrhoea.

Understanding POI requires a clear distinction from natural menopause: this is not early ageing — it is the absence of oestrogen a woman should still be producing for another decade or more. That distinction drives every management decision that follows.

A. Core clinical — the AU general-practice framework

Diagnostic criteria

Per the ESHRE 2024 POI Guideline (Webber et al.), the three diagnostic elements are:

Element	Criterion
Age	Under 40 years
Menstrual	Oligo- or amenorrhoea ≥4 months
Biochemical	FSH >25 IU/L on 2 occasions ≥4 weeks apart

Two key practical points: (1) FSH must be tested off hormonal contraception for at least six weeks — the pill suppresses FSH and will mask the diagnosis; (2) a single elevated FSH is insufficient — a second sample four-plus weeks later is required before the diagnosis is confirmed.

Aetiology

• Idiopathic: 70–90% of cases have no identifiable cause after full workup
• Genetic: Turner syndrome 45,X / mosaicism; FMR1 premutation (found in 0.8–7% of idiopathic POI); other gene mutations (FOXL2, BMP15)
• Autoimmune: thyroid autoimmunity (~20%); adrenal autoimmunity / Addison’s disease (~5% of POI); APS types 1 and 2
• Iatrogenic: chemotherapy (alkylating agents carry highest risk), pelvic radiation, bilateral oophorectomy, endometriosis cystectomies — this category is increasing as childhood cancer survival improves
• Infection: mumps oophoritis (now rare with vaccination); TB; HIV

Cause workup — what to investigate

Once the FSH is confirmed twice, the following workup is recommended per ESHRE 2024:

Karyotype: for all women under 30 and any woman with primary amenorrhoea — Turner mosaicism may be subtle; Y-chromosome material requires gonadectomy due to gonadoblastoma risk. Consider on a case-by-case basis in idiopathic POI aged 30–40.

FMR1 premutation testing: for all idiopathic POI — this identifies women at risk of fragile X syndrome in their children and nephews, and allows cascade family testing. Pre-test genetic counselling is recommended; Medicare rebate criteria apply (confirm with the laboratory).

Autoimmune screen:

• TSH + TPO antibodies — thyroid autoimmunity
• 21-hydroxylase antibodies — positive in ~4% of POI and predicts Addison’s disease; if positive, refer endocrinology for a short Synacthen test
• Tissue transglutaminase antibodies if coeliac symptoms present

Pelvic ultrasound: to assess ovarian volume and antral follicle count; exclude structural causes.

Baseline before HRT: FBC, fasting lipids, LFTs, HbA1c, blood pressure; 25-OH vitamin D; DXA bone densitometry — POI is a Medicare-rebatable indication for DXA regardless of age, per Healthy Bones Australia.

Pitfalls to avoid:

• Testing FSH while on the combined oral contraceptive pill — wait six weeks off the pill
• Missing the 25% of women with POI who have no vasomotor symptoms
• Not testing FMR1 in idiopathic POI — family implications are missed
• Not karyotyping women under 30 — Y material is a gonadectomy indication
• Missing Addison’s disease — adrenal crisis can be life-threatening

Delivering the diagnosis

POI is often emotionally devastating — the news carries implications for fertility, ageing, and identity that patients have rarely anticipated. ESHRE 2024 recommends allowing at least two or three consultations to consolidate the information. Written resources, a referral to an infertility-trained counsellor, and connection with peer support (see below) are part of the standard of care — not optional extras.

B. HRT — essential, not elective

The strongest and most consistent message from ESHRE 2024 and the Australasian Menopause Society is that HRT to approximately age 51 is essential unless there is a genuine contraindication. The risk-benefit calculation is fundamentally different from HRT initiated after natural menopause:

• The patient is replacing absent physiological oestrogen, not supplementing post-baseline levels
• Without HRT, bone density declines rapidly — peak bone mass may not yet be fully achieved
• CVD risk is approximately doubled compared to women without POI if untreated
• The breast cancer risk on HRT in POI does not appear elevated above background until natural menopause age

Preferred regimen (per ESHRE 2024 and eTG):

• Transdermal oestradiol — patch (Estradot 50–100 mcg, Climara) or gel (Sandrena 1–2 mg, Estrogel) — preferred over oral because it carries a lower VTE and stroke risk per the ESTHER study (Lancet, 2007). Dose is typically higher than for postmenopausal HRT
• Progestogen (if uterus intact): Oral micronised progesterone (Prometrium 100–200 mg) or the Mirena IUD — micronised progesterone has the most favourable breast and cardiovascular safety profile; Mirena simultaneously provides contraception (important given the 5–10% spontaneous pregnancy chance)
• Combined oral contraceptive as alternative: provides contraception and symptom control, but the pill-free week leaves women without oestrogen and ethinyloestradiol is less physiological than oestradiol; HRT is generally preferred for bone and cardiovascular protection

HRT is continued until approximately age 51, at which point the decision to continue follows the standard menopause framework — taking into account symptoms, personal preferences, and individual risk profile.

Contraindications (apply the same framework as postmenopausal HRT): current or recent breast cancer; active VTE (transdermal route is often still feasible with specialist advice); active liver disease; unexplained vaginal bleeding.

C. Bone health, cardiovascular health, and fertility

Bone health

• DXA baseline at diagnosis; repeat every two to three years on HRT, more frequently if Z-score is low
• Calcium 1,000–1,200 mg per day (food first — dairy, fortified plant milks, leafy greens; supplement only if dietary intake is inadequate)
• Vitamin D 1,000–2,000 IU daily if deficient (target 25-OH ≥50 nmol/L)
• Weight-bearing and resistance exercise three to five sessions per week
• Bisphosphonates — second-line if HRT is contraindicated or established osteoporosis despite HRT; specialist input recommended given the patient’s young age and reproductive implications (bisphosphonates have prolonged skeletal retention — preconception counselling is essential)

Cardiovascular health

POI confers approximately twice the CVD risk of age-matched women with normal ovarian function when left untreated. HRT to age 51 mitigates a large component of this excess risk. Annual review of blood pressure, fasting lipids, glucose, weight, and smoking status is appropriate — standard cardiovascular calculators under-estimate risk in young women with POI.

Fertility and contraception

5–10% spontaneous pregnancy remains possible even after confirmed POI — this cannot be reliably predicted from hormone levels. Women who do not wish to become pregnant require effective contraception; the Mirena serves the dual purpose of progestogen for HRT and contraception.

For women who desire pregnancy: refer to a fertility specialist. Egg donation IVF achieves approximately 50% live birth per cycle and is the gold standard. Australia’s altruistic-only donation framework means waiting times can be significant — early referral is preferred.

Oncofertility: for any woman of reproductive age facing gonadotoxic treatment (chemotherapy, pelvic radiation), an urgent referral to a fertility specialist for embryo or oocyte cryopreservation must be offered before treatment begins. Failure to offer this referral carries medico-legal risk. Australian fertility centres include Monash IVF, IVF Australia, Genea, and public services — most centres offer urgent appointments for this indication.

D. Australian operations

Medicare items:

• GPCCMP (item 965 / review 967) — POI qualifies as a chronic condition with multi-system implications (bone, cardiovascular, mental health, fertility); enables allied health referrals for exercise physiologist (item 10953), dietitian (10954), and psychologist (10956/10960)
• Mental Health Care Plan item 2715 / review 2717 — grief, depression, anxiety, and sexual dysfunction are common; low threshold to prepare a plan
• DXA bone densitometry (item 12306) — POI is a recognised Medicare under-70 indication
• Heart Health Check (item 699) — POI increases CVD risk; CV risk assessment is appropriate
• FSH, LH, oestradiol (items in the 66695 range); TSH (66716); FMR1 and karyotype (73289 range — confirm current Medicare eligibility with the laboratory)
• Pelvic ultrasound (items 55065 range)
• BreastScreen Australia — free two-yearly mammography from age 50 (eligible from 40)

PBS: All oestradiol formulations (oral, transdermal patch, gel) and micronised progesterone are general schedule. Synthetic progestogens, tibolone, topical vaginal oestrogen, and the combined oral contraceptive are general schedule. Bisphosphonates and denosumab require Authority for osteoporosis criteria.

E. Special populations

Iatrogenic POI after cancer treatment: Women who received gonadotoxic chemotherapy or radiotherapy as children, adolescents, or adults represent an increasing cohort as cancer survival improves. Fertility preservation options should have been offered before treatment; if not, the conversation about donor egg IVF is still possible. HRT remains appropriate and important after cancer treatment in most cases — oncologist involvement in the decision is standard for hormone-sensitive cancers.

Young women with primary amenorrhoea: If a girl reaches age 16 without menarche, or age 14 with no secondary sexual development, investigation includes karyotype and hormone profile. Turner syndrome (45,X or mosaic) is the commonest genetic cause of primary ovarian insufficiency — cardiac and renal anomalies require screening by a specialist team.

Aboriginal and Torres Strait Islander women: Access to genetic testing, fertility services, and specialist gynaecology is significantly more limited in rural and remote areas. Telehealth pathways for HRT initiation and review (MBS existing-relationship 12-month rule applies) and coordination with Aboriginal Community Controlled Health Organisations are appropriate. Cultural sensitivity around fertility loss is essential.

When to escalate

Refer to relevant specialists when:

• Diagnosis is confirmed → gynaecologist or menopause specialist for HRT optimisation and fertility planning
• Positive 21-hydroxylase antibodies → endocrinology for Synacthen test and Addison’s disease workup
• Karyotype abnormality (Turner, Y material) or positive FMR1 premutation → clinical genetics for cascade family testing and gonadectomy planning
• Pregnancy desired → fertility specialist for egg donation IVF or oncofertility
• Gonadotoxic treatment planned → fertility specialist urgently, before first cycle

Urgent / emergency: adrenal crisis features in autoimmune POI (profound fatigue, postural dizziness, pigmentation, hyponatraemia) — this is an endocrine emergency. Severe suicidality in response to infertility diagnosis — safety assessment and crisis support.

What this article is and is not

This is general health information drawn from the ESHRE 2024 POI guideline, Australasian Menopause Society, RANZCOG, eTG, AMH, and Healthy Bones Australia / RACGP 2024 Osteoporosis guideline. It is not personal medical advice and does not create a doctor–patient relationship. HRT decisions are individualised with your own GP and treating specialist.

For peer support and patient information: Australasian Menopause Society — POI patient resources, Jean Hailes — Early menopause / POI, DAISY Network — international POI peer support, HealthDirect — Early menopause, and Healthy Bones Australia.

---

Sources cited

1. Webber L et al. — ESHRE Guideline on POI 2024, Human Reproduction
2. Australasian Menopause Society — POI Position Statement and patient resources
3. RANZCOG — POI clinical updates
4. Therapeutic Guidelines (eTG) — Reproductive health: POI
5. Australian Medicines Handbook (AMH)
6. Healthy Bones Australia + RACGP 2024 Osteoporosis Guideline
7. RACGP — Women’s health resources
8. Canonico M et al. — ESTHER study (transdermal vs oral oestrogen VTE), Lancet 2007
9. ASCIA — autoimmune polyendocrine syndromes guidance
10. Jean Hailes — Early menopause / POI
11. HealthDirect — Early menopause
12. DAISY Network — POI peer support
13. Healthy Bones Australia — consumer resources